

28<sup>th</sup> September, 2022

<p><b>To,</b> <b>Department of Corporate Services</b> <b>Bombay Stock Exchange Ltd.</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p><b>Ref.: Scrip Code No. : 540701</b></p>	<p><b>To,</b> <b>The Manager,</b> <b>Listing Department,</b> <b>National Stock Exchange of India Ltd.</b> “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p><b>Ref. : (i) Symbol – DCAL</b> <b>(ii) Series – EQ</b></p>
--	--

**Sub.: Announcement: Company’s wholly-owned subsidiary viz. CARBOGEN AMCIS AG. successfully completed Swissmedic inspection of its facility in Vionnaz, Switzerland**

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that Company’s wholly owned subsidiary namely CARBOGEN AMCIS AG., Switzerland has successfully completed the Swissmedic inspection of its facility in Vionnaz, Switzerland.

In this regard, please find enclosed herewith Press Release on the captioned subject.

Kindly take the same on your record.

Thanking You,

Yours faithfully,  
**For, Dishman Carbogen Amcis Limited**

**Shrima Dave**  
**Company Secretary**

Encl.: As above

## PRESS RELEASE

---

### **Dishman Carbogen Amcis Ltd announces that its subsidiary, CARBOGEN AMCIS AG, has successfully completed Swissmedic inspection of its facility in Vionnaz, Switzerland**

**Ahmedabad, India (September Day, 2022) — Switzerland-based CARBOGEN AMCIS AG., a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces that its site in Vionnaz, Switzerland has successfully completed a Swissmedic inspection performed by Regional Medicines Inspectorate of Western Switzerland (ISOPTh).**

The two-day inspection took place from September 20<sup>th</sup> to 21<sup>st</sup>, 2022 and was undertaken by an inspector of Regional Medicines Inspectorate of Western Switzerland (ISOPTh) at the Vionnaz, Switzerland, site. The routine inspection covered the Quality Management System compliance and no critical deviation were raised.

This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.

“I am very pleased by the positive outcome of the inspection,” said Pascal Villemagne, CEO of CARBOGEN AMCIS. “It’s a great achievement for our Vionnaz site and rewards the constant excellent work and commitment to quality of our dedicated team, maintaining our successful audit history.”

The facility was acquired by CARBOGEN AMCIS in 2014 and is designed to develop and manufacture highly potent active pharmaceutical ingredients (API) including the capability to produce highly potent warheads and linkers for antibody drug conjugates (ADC).

\*\*\*\*

CARBOGEN AMCIS AG ([www.carbogen-amcis.com](http://www.carbogen-amcis.com)) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Limited., Ahmedabad, India.

Dishman Carbogen Amcis Limited ([imdc.com](http://imdc.com)) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, in China and in India.